The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PROCLAIM-001: A first-in-human trial to assess tolerability of the protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and lymphomas.
 
Alexander I. Spira
Honoraria - ARIAD; Clovis Oncology; Novartis; Roche
Consulting or Advisory Role - ARIAD; Clovis Oncology; Roche/Genentech
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Ignyta (Inst); Incyte (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - ARIAD; Clovis Oncology; Roche
 
Mark R. Middleton
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Agalimmune; Amgen; Bristol-Myers Squibb; Clovis Oncology; CytomX Therapeutics; GlaxoSmithKline; Immunocore; Medicenna; Merck; RigonTEC; Roche; Takeda
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Eisai; GlaxoSmithKline; Immunocore; MedImmune; Merck; Pfizer; Regeneron; RigonTEC; Roche; Takeda; Vertex
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Aung Naing
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Baxter (I); EMD Serono; Healios; Incyte; Karyopharm Therapeutics; MedImmune; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Karen A. Autio
Research Funding - ARMO BioSciences; GlaxoSmithKline; Lilly; Merck; Pfizer
 
John J. Nemunaitis
Employment - Gradalis
Leadership - Gradalis
Stock and Other Ownership Interests - Gradalis
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - Amgen; AstraZeneca
Speakers' Bureau - Amgen; AstraZeneca
Patents, Royalties, Other Intellectual Property - Gradalis
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Baxalta; Takeda
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Michael Gordon
No Relationships to Disclose
 
Rachel W. Humphrey
Employment - CytomX Therapeutics
Leadership - CytomX Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics
Honoraria - Merck Serono
Consulting or Advisory Role - CytomX Therapeutics
Other Relationship - Kyowa Hakko Kirin (I)
 
Chihunt Wong
Employment - CytomX Therapeutics; Unity Biotechnology (I)
Stock and Other Ownership Interests - CytomX Therapeutics
 
Naiyer A. Rizvi
Stock and Other Ownership Interests - Gritstone Bio
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Sharp & Dohme; Novartis; Pfizer